| Signaling via the NFκB system S Mitchell, J Vargas, A Hoffmann Wiley Interdisciplinary Reviews: Systems Biology and Medicine 8 (3), 227-241, 2016 | 1014 | 2016 |
| Transient nuclear envelope rupturing during interphase in human cancer cells JD Vargas, EM Hatch, DJ Anderson, MW Hetzer Nucleus 3 (1), 88-100, 2012 | 265 | 2012 |
| Recruitment of functionally distinct membrane proteins to chromatin mediates nuclear envelope formation in vivo DJ Anderson, JD Vargas, JP Hsiao, MW Hetzer Journal of cell biology 186 (2), 183-191, 2009 | 126 | 2009 |
| Network dynamics determine the autocrine and paracrine signaling functions of TNF AB Caldwell, Z Cheng, JD Vargas, HA Birnbaum, A Hoffmann Genes & development 28 (19), 2120-2133, 2014 | 102 | 2014 |
| CB-6644 is a selective inhibitor of the RUVBL1/2 complex with anticancer activity VA Assimon, Y Tang, JD Vargas, GJ Lee, ZY Wu, K Lou, B Yao, ... ACS chemical biology 14 (2), 236-244, 2019 | 67 | 2019 |
| Anatomy of a negative feedback loop: the case of IκBα R Fagerlund, M Behar, KT Fortmann, YE Lin, JD Vargas, A Hoffmann Journal of The Royal Society Interface 12 (110), 20150262, 2015 | 43 | 2015 |
| Limited specificity of IRF3 and ISGF3 in the transcriptional innate-immune response to double-stranded RNA DR Ourthiague, H Birnbaum, N Ortenlöf, JD Vargas, R Wollman, ... Journal of Leucocyte Biology 98 (1), 119-128, 2015 | 41 | 2015 |
| Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor B Roux, C Vaganay, JD Vargas, G Alexe, C Benaksas, B Pardieu, ... Science translational medicine 13 (587), eabg1168, 2021 | 33 | 2021 |
| Functional importance of stripping in NFκB signaling revealed by a stripping-impaired IκBα mutant HE Dembinski, K Wismer, JD Vargas, GW Suryawanshi, N Kern, G Kroon, ... Proceedings of the National Academy of Sciences 114 (8), 1916-1921, 2017 | 33 | 2017 |
| Type 2 Intramolecular Nitroso Diels− Alder Reaction. Synthesis and Structure of Bridgehead Oxazinolactams SM Sparks, JD Vargas, KJ Shea Organic Letters 2 (10), 1473-1475, 2000 | 30 | 2000 |
| A multi-scale approach reveals that NF-κB cRel enforces a B-cell decision to divide. HA Shokhirev MN, Almaden J, Davis-Turak J, Birnbaum HA, Russell TM, Vargas JA Mol Syst Biol. 11 (1), 783, 2015 | 29 | 2015 |
| A p97/valosin-containing protein inhibitor drug CB-5083 has a potent but reversible off-target effect on phosphodiesterase-6 H Leinonen, C Cheng, M Pitkänen, CL Sander, J Zhang, S Saeid, ... Journal of Pharmacology and Experimental Therapeutics 378 (1), 31-41, 2021 | 21 | 2021 |
| DEAF1 binds unmethylated and variably spaced CpG dinucleotide motifs PJ Jensik, JD Vargas, SN Reardon, S Rajamanickam, JI Huggenvik, ... PloS one 9 (12), e115908, 2014 | 17 | 2014 |
| VCP/p97 inhibitor CB-5083 modulates muscle pathology in a mouse model of VCP inclusion body myopathy C Cheng, L Weiss, H Leinonen, A Shmara, HZ Yin, T Ton, A Do, J Lee, ... Journal of translational medicine 20 (1), 21, 2022 | 9 | 2022 |
| Comparative oncology assessment of a novel inhibitor of valosin-containing protein in tumor-bearing dogs AK LeBlanc, CN Mazcko, TM Fan, DM Vail, BK Flesner, JN Bryan, S Li, ... Molecular cancer therapeutics 21 (10), 1510-1523, 2022 | 5 | 2022 |
| Trials in progress: a phase I study to evaluate the safety and pharmacokinetic profiles of CB-5339 in participants with relapsed/refractory acute myeloid leukemia or relapsed … L Benajiba, HE Carraway, N Hamad, EM Stein, CK Yannakou, ... Blood 136, 21, 2020 | 5 | 2020 |
| VCP/p97 INHIBITOR FOR THE TREATMENT OF CANCER MJ Stuart, R Le Moigne, DJ Anderson, M Rolfe, KL Rajangam, ... US Patent App. 17/998,336, 2023 | | 2023 |
| Efficacy of Vcp/p97 Inhibitor, CB-5339, Alone and in Combinations Against High-Risk AML, Including Those with Genetic Lesion in TP53 WC Fiskus, K Das, CP Mill, CE Birdwell, JA Davis, K Philip, N Alhamadani, ... Blood 140 (Supplement 1), 8807-8808, 2022 | | 2022 |
| Targeting AML dependency on VCP-mediated DNA repair through a selective second-generation small molecule inhibitor B Roux, C Vaganay, JD Vargas, G Alexe, C Benaksas, B Pardieu, ... Science Translational Medicine, 2021 | | 2021 |
| Targeting AML dependency on VCP-mediated DNA repair through a highly selective second-generation small molecule inhibitor L Benajiba, J Vargas, G Alexe, C Vaganay, B Roux, JJ Kiladjian, ... FUNDAMENTAL & CLINICAL PHARMACOLOGY 35, 205-206, 2021 | | 2021 |
Alexander HoffmannUCLA在 ucla.edu 的电子邮件经过验证
